REHOVOT, Israel, April 25,
2022 /PRNewswire/
-- CollPlant (Nasdaq: CLGN), a regenerative
and aesthetics medicine company developing innovative technologies
and products for tissue regeneration and organ manufacturing, today
announced that CEO Yehiel Tal will
moderate the International Society for Biofabrication's (ISBF)
virtual event on May 2nd.
Mr. Tal also serves as a board member of ISBF.
The event will be hosted by the ISBF's Industry Relations
Committee and feature experts in the field from academia and
industry: Dr. Daniel Levner,
co-founder and CTO of Emulate, Dr. Ben
Maoz from Tel Aviv University,
Dr. Lutz Kloke, founder and CSO of
Cellbricks and Dr. Jeroen Eyckmans
from Boston University. The Q&A
session will be moderated by Ms. Katie
Weimer, VP Regenerative Medicine at 3D systems and a member
of the ISBF's Industry Relations Committee.
Event title: Biofabrication of Microphysiological Systems
for Drug Discovery and Screening - Future Outlook
Date: Monday, May 2, 2022
Time: 10:00 AM EST /
4:00 PM CET / 11:00 PM JST
Location: Virtual event
Registration link
The Industry Relations Committee of ISBF is serving as a
mediator of academia-industry and industry-industry to promote and
stimulate collaboration; developing mechanisms to facilitate
translation of laboratory discoveries into manufactured products;
and representing the industry in all Biofabrication aspects
including roadmap, technologies, cell biology, large scale
manufacturing, regulation, and commercialization.
For more details and to register, please
visit https://biofabricationsociety.org/
About the International Society for Biofabrication
From basic science to medical applications, the biofabrication
community convened at the International Conference on
Biofabrication (Biofabrication 2019). The field of biofabrication
is dedicated to researching and integrating technologies such as
bio-printing, bio-plotting, and bio-assembly into applications such
as engineered tissue systems and regenerative medicine. The
International Society for Biofabrication's (ISBF) core purpose is
to foster scientific and technological innovation and excellence
for the benefit of humanity. ISBF promotes the interaction between
and convergence in the different disciplines of the field of
Biofabrication, as well as between basic research and applied
practice. Further, the Society aims to promote the cooperation with
other scientific organizations and communities.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. The Company's products are based on its rhCollagen
(recombinant human collagen) produced with CollPlant's proprietary
plant based genetic engineering technology. These products address
indications for the diverse fields of tissue repair, aesthetics,
and organ manufacturing, and are ushering in a new era in
regenerative and aesthetic medicine.
At the beginning of 2021, CollPlant entered into a development
and global commercialization agreement for dermal and soft tissue
fillers with Allergan, an AbbVie company, the global leader in the
dermal filler market. Later in 2021, CollPlant entered a strategic
co-development agreement with 3D Systems for a 3D bioprinted
regenerative soft tissue matrix for use in breast reconstruction
procedures in combination with an implant.
For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the impact of the COVID-19
pandemic; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk and products for
medical aesthetics; the Company's ability to obtain favorable
pre-clinical and clinical trial results; regulatory action with
respect to rhCollagen based BioInk and medical aesthetics products
including but not limited to acceptance of an application for
marketing authorization review and approval of such application,
and, if approved, the scope of the approved indication and
labeling; commercial success and market acceptance of the Company's
rhCollagen based products in 3D Bioprinting and medical aesthetics;
the Company's ability to establish sales and marketing capabilities
or enter into agreements with third parties and its reliance on
third party distributors and resellers; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the Company's reliance on third parties to conduct
some or all aspects of its product manufacturing; the scope of
protection the Company is able to establish and maintain for
intellectual property rights and the Company's ability to operate
its business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the Company operates;
projected capital expenditures and liquidity; changes in the
Company's strategy; and litigation and regulatory proceedings. More
detailed information about the risks and uncertainties affecting
CollPlant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the
SEC, and in other filings that CollPlant has made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's current views with respect to future
events, and CollPlant does not undertake and specifically disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
Photo
- https://mma.prnewswire.com/media/1803235/CollPlant_to_moderate_ISBF.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/collplant-ceo-yehiel-tal-to-moderate-isbfs-virtual-event-on-biofabrication-of-microphysiological-systems-for-drug-discovery-and-screening-301531675.html
SOURCE CollPlant